AstraZeneca and MSD have announced that the companies have received marketing authorisation from China’s National Medical Products Administration (NMPA) for Lynparza (olaparib) as a 1st-line maintenance treatment of adult patients
Nordic Life Science
NLS Pharma News
Pharma
Bonnier Ventures, the venture arm of the Bonnier group, has taken the lead in the USD 1.3 million investment round in Pilloxa. Pilloxa, founded in 2015, has developed a patient
The Harvard Business Review (HBR) has selected Pascal Soriot among the Top 100 Best Performing CEOs in the world for 2019, and one of only three CEOs from a biopharmaceutical
Orexo has acquired the exclusive US rights to vorvida, a digital therapy for the treatment of Alcohol Use Disorder (AUD), from GAIA. This news follows an earlier agreement with GAIA
The US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). The US approval was granted under
MetaCurUm Biotech has won an innovation competition announced by Groth & Co. MetaCurUm Biotech develops a new treatment of aggressive cancer. The company is a spin-off from Umeå University and
Clinical trials
GeNeuro has announced a collaboration for a new clinical trial of temelimab in multiple sclerosis (MS) with clinical researchers of
Scandinavian Biopharma reports successful results of the ETEC vaccine candidate ETVAX in a placebo-controlled phase I/II study in infants and
Follicum has announced that the company has signed a collaboration agreement with proDERM for conducting the new clinical trial with
LIDDS licensee Jiangxi Puheng Pharma has after reviewing the preliminary results in LPC-004 decided to move ahead and has initiated
Vaccibody has announced strong preliminary data from the ongoing VB N-01 phase I/IIa clinical trial of the VB10.NEO neoantigen cancer
LIDDS has received approval from authorities in Lithuania to conduct its Phase I study, NZ-DTX-001. The aim of the phase
Gedea Biotech reports that all 24 patients have been treated with its lead product, pHyph, a vaginal tablet for topical
Medivir has announced that the first patient has been enrolled in a phase I study to investigate the safety and
The company has announced results from a preclinical study examining ilixadencel, an off-the-shelf, cell-based immune primer, tested in combination with
Data from a voluntary open label extension (OLE) study indicates longer PSA effect with Liproca Depot in prostate cancer patients
The company has initiated the first-in-human trial of MVA-BN WEV, a prophylactic vaccine candidate against the equine encephalitis virus –
The first cohort of 40 adults was enrolled in the company’s Phase I study in Zambia. The study is part
During its first year the bioprocess pilot-scale facility in Uppsala has hosted fifteen national and international projects and more than
The company has announced that the last patient has been included in the OP-106 HORIZON phase 2 clinical study evaluating
The company has reported the first results from their Proof of Concept STAR study in subjects with prediabetes or newly
The Oslo University Hospital, has been included as a site in the ongoing ONCOS-102 trial in anti-PD1 refractory, advanced melanoma.
Profiles in Pharma
Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new
She joined LEO Pharma by chance, more than 27 years ago, but she remained there, for the true focus on
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments